PI3K signaling pathway in colorectal cancer

Abstract

Wang Hao, Zhang Qingling. PI3K signaling pathway in colorectal cancer[J]. Journal of International Oncology, 2016, 43(8): 631-633.

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262. ［2］ Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting［J］. Nat Rev Cancer, 2015, 15(1): 7-24. DOI: 10.1038/nrc3860. ［3］ Kato S, Iida S, Higuchi T, et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer［J］. Int J Cancer, 2007, 121(8): 1771-1778. DOI: 10.1002/ijc.22890. ［4］ Ogino S, Liao X, Imamura Y, et al. Predictive and prognostic analysis of PIK3CA mutation in stage Ⅲ colon cancer intergroup trial［J］. J Natl Cancer Inst, 2013, 105(23): 1789-1798. DOI: 10.1093/jnci/djt298. ［5］ Kaur J, Sanyal SN. PI3kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac［J］. Tumour Biol, 2010, 31(6): 623-631. DOI: 10.1007/s13277-010-0078-9. ［6］ Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectalcancer survival［J］. N Engl J Med, 2012, 367(17): 1596-1606. DOI: 10.1056/NEJMoa1207756. ［7］ Domingo E, Church DN, Sieber O, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal antiinflammatory drug therapy in colorectal cancer［J］. J Clin Oncol, 2013, 31(34): 4297-4305. DOI: 10.1200/JCO.2013.50.0322. ［8］ Van Cutsem E, Khne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colo-rectal cancer: updated analysis of overall survival according to tumor K-RAS and BRAF mutation status［J］. J Clin Oncol, 2011, 29(15): 2011-2019. DOI: 10.1200/JCO.2010.33.5091. ［9］ SartoreBianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFRtargeted monoclonal antibodies［J］. Cancer Res, 2009, 69(5): 1851-1857. DOI: 10.1158/0008-5472.CAN-08-2466. ［10］ Mao M, Tian F, Mariadason JM, et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents［J］. Clin Cancer Res, 2013, 19(3): 657-667. DOI: 10.1158/1078-0432.CCR-11-1446. ［11］ Zhu YF, Yu BH, Li DL, et al. PI3K expression and PIK3CA mutations are related to colorectal cancer metastases［J］. World J Gastroenterol, 2012, 18(28): 3745-3751. DOI: 10.3748/wjg.v18.i28.3745. ［12］ Wang G, Wang F, Ding W, et al. April induces tumorigenesis and metastasis of colorectal cancer cells via activation of the PI3K/Akt pathway［J］. PLoS One, 2013, 8(1): e55298. DOI: 10.1371/journal.pone.0055298. ［13］ Lan YT, Jen-Kou L, Lin CH, et al. Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers［J］. J Surg Oncol, 2015, 111(7): 905-910. DOI: 10.1002/jso.23895. ［14］ Bendell JC, Rodon J, Burris HA, et al. Phase I, doseescalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors［J］. J Clin Oncol, 2012, 30(3): 282-290. DOI: 10.1200/JCO.2011.36.1360. ［15］ Hong DS, Bowles DW, Falchook GS, et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors［J］. Clin Cancer Res, 2012, 18(15): 4173-4182. DOI: 10.1158/1078-0432.CCR-12-0714. ［16］ Sarker D, Ang JE, Baird R, et al. Firstinhuman phase I study of pictilisib (GDC0941), a potent panclass I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors［J］. Clin Cancer Res, 2015, 21(1): 77-86. DOI: 10.1158/1078-0432.CCR-14-0947. ［17］ Roper J, Richardson MP, Wang WV, et al. The dual PI3K/mTOR inhibitor NVPBEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wildtype colorectal cancer［J］. PLoS One, 2011, 6(9): e25132. DOI: 10.1371/journal.pone.0025132. ［18］ Migliardi G, Sassi F, Torti D, et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patientderived xenografts of RASmutant colorectal carcinomas［J］. Clin Cancer Res, 2012, 18(9): 2515-2525. ［19］ Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer［J］. J Clin Oncol, 2010, 28(6): 1075-1083. DOI: 10.1200/JCO.2009.25.3641. ［20］ Yap TA, Yan L, Patnaik A, et al. Firstinman clinical trial of the oral panAKT inhibitor MK2206 in patients with advanced solid tumors［J］. J Clin Oncol, 2011, 29(35): 4688-4695. DOI: 10.1200/JCO.2011.35.5263. ［21］ Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition［J］. Sci Signal, 2009, 2(67): pe24. DOI: 10.1126/scisignal.267pe24. ［22］ Wolpin BM, Ng K, Zhu AX, et al. Multicenter phase Ⅱ study of tivozanib (AV951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer［J］. Oncologist, 2013, 18(4): 377-378. DOI: 10.1634/theoncologist.2012-0378. ［23］ Spindler KL, Sorensen MM, Pallisgaard N, et al. Phase Ⅱ trial of temsirolimus alone and in combination with irinotecan for K-RAS mutant metastatic colorectal cancer: outcome and results of K-RAS mutational analysis in plasma［J］. Acta Oncol, 2013, 52(5): 963970. DOI: 10.3109/0284186X.2013.776175. ［24］ Altomare I, Hurwitz H. Everolimus in colorectal cancer［J］. Expert Opin Pharmacother, 2013, 14(4): 505-513. DOI: 10.1517/14656566.2013.770473. ［25］ Shimizu T, Tolcher AW, Papadopoulos KP, et al. The clinical effect of the dualtargeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer［J］. Clin Cancer Res, 2012, 18(8): 2316-2325. DOI: 10.1158/1078-0432.CCR-11-2381.

[1]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Yue Hongyun, Zhang Baihong.Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113.
[5]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[6]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[7]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474.
[8]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[9]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[10]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing.Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer[J]. Journal of International Oncology, 2023, 50(5): 268-273.
[11]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun.Construction of postoperative prognosis model for patients with colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 157-163.
[12]	Xu Liangfu, Li Yuanfei.Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 186-190.
[13]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng.Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer[J]. Journal of International Oncology, 2023, 50(12): 717-722.
[14]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu.Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer[J]. Journal of International Oncology, 2023, 50(11): 683-687.
[15]	Wang Xi, Wu Chuanqing.Research progress in reversing multidrug resistance in colorectal cancer[J]. Journal of International Oncology, 2023, 50(1): 42-46.

PI3K signaling pathway in colorectal cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments